investors

Investor Information

We are a reporting company in Canada and file with the Canadian Securities Administrators our annual reports with annual financial statements, interim reports, management information, circulars (proxy statements), press releases, and other items, which are publicly available on SEDAR at www.sedar.com.

To speak to our investor relations representative, please contact Babak Pedram at 416-644-5081.

To be put on our email list for the latest company news, please send your name, telephone number and email address to akrantz@advancedproteome.com


CUSIP: 007628


Year End: July 31


Shares Issued and Outstanding: As of April 1, 2016 – 112,880,418


Transfer Agent: Computershare Investor Services Inc.


Officers and Directors: Allen Krantz, Ph.D.
CEO/President
Director and Corporate Secretary

Randal Chase
Director

Jean Bellin
Director

Gary W Hayes, MD
Director

Kenneth C. Phillippe
CFO


Scientific Advisory Board: Prof. Paul A. Wender
Stanford University

Prof. Stephen Hanessian
University of Montreal

Prof. Stephen G. Withers
University of British Columbia

Audit Committee: Jean Bellin
Chair, Audit Committee

Allen Krantz, Ph.D.

Gary W, Hayes, MD


Compensation Committee: Jean Bellin

Gary W, Hayes, MD


Corporate Advisory Board:

Paul Woodward
President - Conation Capital Corp.

David Webb, Ph.D.
Adjunct Prof. - The Scripps Research Institute

John R. Garrett, Ph.D.
co-Ceo - Glycosyn LLC


Auditor: Dale Matheson
Carr-Hilton LaBonte LLP


Investor Contact: Babak Pedram
Investor Relations
Virtus Advisory Group Inc.

Phone: 416-644-5081
Email: bpedram@virtusadvisory.com


Sedar Filings

SEDAR is the official site that provides access to most public securities documents and information filed by public companies and investment funds with the Canadian Securities Administrators (CSA) in the SEDAR filing system. The statutory objective in making public this filed information is to enhance investor awareness of the business and affairs of public companies and investment funds and to promote confidence in the transparent operation of capital markets in Canada.

You may access our public filed documents on SEDAR at www.sedar.com


Financials

For a complete listing of financials please visit SEDAR

Disclaimer

This website contains historical and forward-looking statements. The forward-looking statements involve risks and uncertainties. Forward looking statements appearing on this website in this presentation represent management's current estimates at the time they were posted and these may change significantly as new information comes to hand. The information contained in this website has been obtained by Advanced Proteome Therapeutics Corporation. from its own records and from other sources believed to be reliable, however no representation or warranty is made as to its accuracy or completeness. Reference should be made to the Company's most recent Annual Report filed with Canadian securities regulatory authorities (and available at www.sedar.com) for a description of the major risk factors.

Advanced Proteome Therapeutics Corporation.

Suite 113
650 Albany Street
Boston, Massachusetts
02118 USA

T 617-638-0340
F 617-638-0341
www.advancedproteome.com
akrantz@advancedproteome.com